Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
51.34
+0.16 (0.31%)
At close: Feb 11, 2026, 4:00 PM EST
51.34
0.00 (0.00%)
After-hours: Feb 11, 2026, 4:32 PM EST
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $192.10M in the quarter ending September 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $681.54M, up 4.54% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$681.54M
Revenue Growth
+4.54%
P/S Ratio
4.20
Revenue / Employee
$1,011,185
Employees
674
Market Cap
2.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
| Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
| Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
| Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
| Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
| Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
| Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
| Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
| Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
| Dec 31, 2011 | 803.00K | 697.00K | 657.55% |
| Dec 31, 2010 | 106.00K | -37.82M | -99.72% |
| Dec 31, 2009 | 37.93M | 29.04M | 326.65% |
| Dec 31, 2008 | 8.89M | 4.66M | 109.97% |
| Dec 31, 2007 | 4.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.03B |
| Perrigo Company | 4.28B |
| Amneal Pharmaceuticals | 2.93B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| HUTCHMED (China) | 602.20M |
SUPN News
- 2 days ago - Lunai Bioworks, Inc. Issues Letter to Shareholders - PRNewsWire
- 10 days ago - Supernus: Outlook For 2026 Positive, Upholding Buy Rating - Seeking Alpha
- 27 days ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 2 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript - Seeking Alpha